3 reports

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Antibiotic Resistance
  • Blood Disease
  • Cancer
  • Digestive System Disorder
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative